BioCentury
ARTICLE | Clinical News

TTI-621: Preliminary Ph Ia data

December 15, 2016 11:17 PM UTC

Preliminary data from 18 patients with relapsed or refractory lymphomas in the dose-escalation Phase Ia portion of an open-label, North American Phase Ia/Ib trial showed that once-weekly IV TTI-621 le...

BCIQ Company Profiles

Trillium Therapeutics Inc.

BCIQ Target Profiles

CD47